New Technologies and Product Launches Drive Strong Revenue Growth and Certifications - Research Report on Hologic, Edwards

    New Technologies and Product Launches Drive Strong Revenue Growth and
 Certifications - Research Report on Hologic, Edwards Lifesciences, Volcano,
                    Opko Health, and Wright Medical Group

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 8, 2013

NEW YORK, August 8, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Hologic
Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: EW), Volcano
Corporation (NASDAQ: VOLC), Opko Health, Inc. (NYSE: OPK), and Wright Medical
Group Inc. (NASDAQ: WMGI). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Hologic Inc. Research Report 

On August 5, 2013, Hologic Inc. (Hologic) reported its Q3 FY 2013 financial
results (period ended June 29, 2013). The Company reported total revenues of
$626.1 million, reflecting a 33.2% YoY growth, driven primarily by inclusion
of Gen-Probe revenues, increased service revenues and higher sales of MyoSure
hysteroscopic tissue removal (MyoSure) systems and breast biopsy products. Net
loss was $11.0 million or $0.04 per diluted share, for the quarter, compared
with net income of $23.6 million or $0.09 per diluted share, in Q3 FY 2012.
Non-GAAP net income was $103.2 million or $0.38 per diluted share, compared to
$92.6 million or $0.35 per diluted share in Q3 FY 2012. "We are pleased our
third quarter revenues were in-line with and our EPS exceeded guidance.
Although we have lowered expectations for the remainder of the fiscal year, I
am confident we have the necessary platforms and breadth of assets to drive
organic growth and deliver strong profitability," said Jack Cumming, President
and Chief Executive Officer of Hologic. The Company anticipates full-year FY
2013 non-GAAP EPS of $1.46 to $1.47. The Full Research Report on Hologic Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d132_HOLX]

--

Edwards Lifesciences Corp. Research Report

On August 5 2013, Edwards Lifesciences Corp. (Edward Lifesciences) announced
that it has received a conditional Investigational Device Exemption (IDE)
approval from the US Food and Drug Administration (FDA) for the initiation of
a clinical trial of its Edwards SAPIEN 3 transcatheter aortic heart valve and
accessories. "This valve builds on the SAPIEN platform and provides new
features designed to benefit patients and enhance ease of use, such as a lower
profile, a fabric cuff intended to reduce paravalvular leak and new delivery
systems," said Larry L. Wood, Corporate Vice President, Transcatheter Heart
Valves at Edward Lifesciences. "We appreciate the FDA's efforts to allow
initiation of this trial in a timely way, providing U.S. patients with access
to our most advanced transcatheter system." The Company informed that the
trial will enroll up to 500 patients to study the SAPIEN 3 valve in the
treatment of high-risk and inoperable patients with severe symptomatic aortic
stenosis. The Full Research Report on Edwards Lifesciences Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/48b8_EW]

--

Volcano Corporation Research Report

On August 5, 2013, Volcano Corp. (Volcano) reported its Q2 2013 financial
results. The Company posted revenues of $101.3 million, up 6.3% YoY during the
quarter. GAAP net loss was $2.4 billion or $0.04 per share in Q2 2013,
compared with net income of $3.3 million or $0.06 per diluted share in Q2
2012. Scott Huennekens, President and Chief Executive Officer of Volcano
commented, "We continue to achieve market share gains and are setting the
stage for future growth with initiatives such as our iFR (Instant Wave-Free
Ratio) FFR technology. The launch of iFR in Europe is going very well and we
just initiated our market launch in Japan." The Company reaffirmed its
full-year 2013 outlook and expects revenues in the range of $394.0 to $400.0
million. The Full Research Report on Volcano Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/14bf_VOLC]

--

Opko Health, Inc. Research Report

On July 24, 2013, Opko Health, Inc. (Opko) announced that its Barcelona based
subsidiary, Pharmadiet, S.L.U. has received a regulatory approval for the
commercialization of its oral and injectable formulations of Citicoline, from
the health authority of Spain, Agencia Española de Medicamentos y Productos
Sanitarios. The Company expects to receive final marketing authorization for
its product within 60 to 90 days. "OPKO plans to commercialize its oral and
injectable citicoline products in Europe, Latin America, and other markets as
well," said Phillip Frost, M.D., Chairman and Chief Executive Officer of Opko.
The Full Research Report on Opko Health, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

--

Wright Medical Group Inc. Research Report 

On August 5, 2013, Wright Medical Group Inc. (Wright Medical) reported its Q2
2013 financial results. The Company posted net sales from continuing
operations of $60.6 million, a 16.6% YoY growth on constant currency basis,
during the quarter. Net loss from continuing operations for the quarter
totaled $15.5 million or $0.34 per diluted share, compared to net loss of $1.4
million or $0.04 per diluted share in Q2 2012. Robert Palmisano, President and
Chief Executive Officer of Wright Medical, commented, "The global foot and
ankle business grew an outstanding 30% driven by continued sales productivity
gains in our U.S. foot and ankle business, positive progress and focus on
international market development and continued strong uptake of recent new
foot and ankle product launches." The Company anticipates full-year 2013 net
sales from continuing operations of c.$235 million to $240 million. The Full
Research Report on Wright Medical Group Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/1782_WMGI]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas - CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.